GlassScriptPhysician profile
San H Thiha
NPI 1285678995
$31,740.75
in general payments reported to CMS, 2019-2025
63 companies · $3,470 in 2025
The $3,470 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,894 · 2020: $2,251 · 2021: $5,724 · 2022: $5,148 · 2023: $4,748 · 2024: $5,506 · 2025: $3,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,724.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,078.52 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $3,923.89 | 2019-2025 | Breztri, Airsupra, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $1,602.73 | 2019-2025 | Opdivo, Abecma, Reblozyl |
| Amgen INC. | $1,570.62 | 2019-2025 | Evenity, Blincyto, Lumakras |
| Glaxosmithkline, LLC. | $1,122.83 | 2020-2024 | Arexvy, Zejula, Shingrix |
| Janssen Biotech, INC. | $1,091.29 | 2019-2025 | Rybrevant, Carvykti, Akeega |
| Incyte Corporation | $1,023.13 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Abbvie INC. | $960.89 | 2019-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $840.57 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $838.60 | 2019-2025 | |
| Genentech USA, INC. | $833.17 | 2019-2023 | Lunsumio |
| Novo Nordisk INC | $642.42 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $585.51 | 2021-2025 | |
| Daiichi Sankyo INC. | $577.71 | 2020-2025 | Enhertu |
| Beigene USA, INC. | $568.00 | 2021-2024 | Brukinsa |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw San Thiha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.